SCOPUS 정보 검색 플랫폼

Volumn 49, Issue 5, 2011, Pages 397-398

Development of an HPLC method for the determination of anidulafungin in human plasma and saline

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79955783728 PISSN: 00219665 EISSN: None Source Type: Journal
DOI: 10.1093/chromsci/49.5.397 Document Type: Article

Times cited : (10)

References (8)

1
- 0013297123
- Pfizer Inc. Eraxis anidulafungin for injection, Pfizer, Inc. New York, NY
- Pfizer Inc. Eraxis (anidulafungin) for injection. Package Insert. Pfizer, Inc. New York, NY. http://media.pfizer.com/files/products/uspi-eraxis.pdf (2009)
- (2009) Package Insert

2
- 70349638070
- In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: A head-to-head comparison using the CLSI M38-A2 broth microdilution method
- M. Pfaller, L. Boyken, R. Hollis, J. Kroeger, S. Messer, S. Tendolkar, and D. Diekema. In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. J. Clin. Microbiol. 47:3323-3325 (2009).
- (2009) J. Clin. Microbiol. , vol.47 , pp. 3323-3325
- Pfaller, M.¹ Boyken, L.² Hollis, R.³ Kroeger, J.⁴ Messer, S.⁵ Tendolkar, S.⁶ Diekema, D.⁷

3
- 66749118328
- Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: Report from the SENTRY antimicrobial surveillance program (2006 to 2007)
- S. Messer, G. Moet, J. Kirby, and R. Jones. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY antimicrobial surveillance program (2006 to 2007). J. Clin. Microbiol. 47:1942-1946 (2009).
- (2009) J. Clin. Microbiol. , vol.47 , pp. 1942-1946
- Messer, S.¹ Moet, G.² Kirby, J.³ Jones, R.⁴

4
- 60549098868
- Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America
- P. Pappas, C. Kauffman, D. Andes, D. Benjamin, T. Calandra, J. Edwards, S. Filler, J. Fisher, B. J. Kullberg, L. Ostrosky-Zeichner, A. Reboli, J. Rex, T. Walsh, and J. Sobel. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535 (2009).
- (2009) Clin. Infect. Dis. , vol.48 , pp. 503-535
- Pappas, P.¹ Kauffman, C.² Andes, D.³ Benjamin, D.⁴ Calandra, T.⁵ Edwards, J.⁶ Filler, S.⁷ Fisher, J.⁸ Kullberg, B.J.⁹ Ostrosky-Zeichner, L.¹⁰ Reboli, A.¹¹ Rex, J.¹² Walsh, T.¹³ Sobel, J.¹⁴

5
- 62949151478
- In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin
- B. Damle, J. Dowell, R. Walsky, G. Weber, M. Stogniew, and P. Inskeep. In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. Antimicrob. Agents Chemother. 53:1149-1156 (2009).
- (2009) Antimicrob. Agents Chemother. , vol.53 , pp. 1149-1156
- Damle, B.¹ Dowell, J.² Walsky, R.³ Weber, G.⁴ Stogniew, M.⁵ Inskeep, P.⁶

7
- 71249104670
- Bronchopulomanry disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults
- J. Crandon, MA. Banevicius, A. Fang, P. Crownover, RF. Knauft, S. Pope, J. Russomanno, E. Shore, D. Nicolau, and J. Kuti. Bronchopulomanry disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Antimicrob. Agents Chemother. 53:5102-5107 (2009).
- (2009) Antimicrob. Agents Chemother. , vol.53 , pp. 5102-5107
- Crandon, J.¹ Banevicius, M.A.² Fang, A.³ Crownover, P.⁴ Knauft, R.F.⁵ Pope, S.⁶ Russomanno, J.⁷ Shore, E.⁸ Nicolau, D.⁹ Kuti, J.¹⁰

8
- 79955753498
- Guidance for Industry Bioanalytical Method Validation. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research CDER, May, BP
- Guidance for Industry Bioanalytical Method Validation. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). May 2001. BP. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm070107.pdf
- (2001) Center for Veterinary Medicine (CVM)

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.